Literature DB >> 23079702

Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation.

Huina Liu1, Huirong Shi, Yibin Hao, Guoqiang Zhao, Xiaofeng Yang, Yali Wang, Mei Li, Min Liu.   

Abstract

The study investigates the effect of FAK, DLC-1 on OVCAR-3 proliferation. FAK gene siRNA vector recombinant plasmid was constructed using RNA interference technique. FAK gene-transfected OVCAR-3 cells, OVCAR-3 cells with DLC-1 gene expression, and OVCAR-3 cells with simultaneous expression of DLC-1 and FAK genes were obtained using gene transfection technology. In addition, siRNA control group and blank control were also given. Effect of FAK, DLC-1 gene expression on OVCAR-3 proliferation was examined by FCM and Cell Counting Kit-8 (CCK-8) methods. Results showed that DLC-1 gene high expression and FAK gene silencing, single silencing FAK gene, and single DLC-1 gene high expression in OVCAR-3 cells may decrease S and G2/M phase proportion of the cell cycle. Moreover, DLC-1 gene high expression and FAK gene silencing in OVCAR-3 cells can display the most significant effect. This confirmed that DLC-1 gene high expression and FAK gene silencing may significantly inhibit the OVCAR-3 cells proliferation. CCK-8 analysis showed that silence FAK gene expression or/and increasing DLC-1 gene expression may decrease OVCAR-3 growth rate. Moreover, simultaneous silence the expression of FAK gene and high expression of DLC-1 gene can display the most significant effect on OVCAR-3 growth. It can be concluded that downregulation of FAK gene expression or/and upregulation of DLC-1 gene expression can all inhibit the OVCAR-3 growth. Moreover, DLC-1 gene expression and FAK gene silencing can display the most marked inhibitory effect on the OVCAR-3 growth.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23079702     DOI: 10.1007/s11033-012-1956-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  Integrin β1 mediates epithelial growth factor-induced invasion in human ovarian cancer cells.

Authors:  Man-Tat Lau; Wai-Kin So; Peter C K Leung
Journal:  Cancer Lett       Date:  2012-03-01       Impact factor: 8.679

2.  Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.

Authors:  Jyotsnabaran Halder; Aparna A Kamat; Charles N Landen; Liz Y Han; Susan K Lutgendorf; Yvonne G Lin; William M Merritt; Nicholas B Jennings; Arturo Chavez-Reyes; Robert L Coleman; David M Gershenson; Rosemarie Schmandt; Steven W Cole; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

Review 3.  Biochemical signals and biological responses elicited by the focal adhesion kinase.

Authors:  M D Schaller
Journal:  Biochim Biophys Acta       Date:  2001-07-25

4.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.

Authors:  M Agochiya; V G Brunton; D W Owens; E K Parkinson; C Paraskeva; W N Keith; M C Frame
Journal:  Oncogene       Date:  1999-10-07       Impact factor: 9.867

6.  The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.

Authors:  Steve Goodison; Jing Yuan; Derek Sloan; Ryung Kim; Cheng Li; Nicholas C Popescu; Virginia Urquidi
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

7.  DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma.

Authors:  Tai Young Kim; Jung Weon Lee; Hwang-Phill Kim; Hyun-Soon Jong; Tae-You Kim; Mira Jung; Yung-Jue Bang
Journal:  Biochem Biophys Res Commun       Date:  2007-01-30       Impact factor: 3.575

8.  Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.

Authors:  Yuliya Pylayeva; Kelly M Gillen; William Gerald; Hilary E Beggs; Louis F Reichardt; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2009-01-19       Impact factor: 14.808

9.  Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.

Authors:  Ming Guan; Xiaoling Zhou; Nikolaos Soulitzis; Demetrios A Spandidos; Nicholas C Popescu
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

10.  Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.

Authors:  Anil K Sood; Jeremy E Coffin; Galen B Schneider; Mavis S Fletcher; Barry R DeYoung; Lynn M Gruman; David M Gershenson; Michael D Schaller; Mary J C Hendrix
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

View more
  4 in total

Review 1.  Fixing the GAP: The role of RhoGAPs in cancer.

Authors:  Gabriel Kreider-Letterman; Nicole M Carr; Rafael Garcia-Mata
Journal:  Eur J Cell Biol       Date:  2022-02-10       Impact factor: 6.020

2.  DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Authors:  Yu-Zheng Xue; Tie-Long Wu; Yan-Min Wu; Ying-Yue Sheng; Zhe-Qiang Wei; Yu-Feng Lu; Li-Hua Yu; Jian-Ping Li; Zhao-Shen Li
Journal:  Tumour Biol       Date:  2013-05-17

3.  MicroRNA-200c and microRNA-31 regulate proliferation, colony formation, migration and invasion in serous ovarian cancer.

Authors:  Fateen Farhana Ibrahim; Rahman Jamal; Saiful Effendi Syafruddin; Nurul Syakima Ab Mutalib; Sazuita Saidin; Reena Rahayu MdZin; Mohammad Manir Hossain Mollah; Norfilza Mohd Mokhtar
Journal:  J Ovarian Res       Date:  2015-08-12       Impact factor: 4.234

4.  Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.

Authors:  Fang Ren; Huirong Shi; Gong Zhang; Ruitao Zhang
Journal:  J Exp Clin Cancer Res       Date:  2013-08-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.